Skip to content
Conference Image

What Lies Beneath: Treating the Trauma Underlying Substance Use

Hybrid
1.5 CE Hour
Clinical
Ticket Pricing
Attending In Person at Ascendant IOP NY
$0
Attending Virtually on TPN.health
$0

Presented By

Brought to You By

Dates and Times

  • -
    In-Person, Live Webinar

Location

Description

For many individuals suffering from substance use disorders, making the decision to enter treatment is a challenging process requiring a great degree of humility and courage. Clients often initially approach treatment with limited knowledge and perspective of what is truly required of themselves to benefit from a residential treatment setting. Not surprisingly, surrendering from their “regular lives” into an often novel and emotionally challenging therapeutic setting will elicit self-protective mechanisms. These reflexive responses can prevent both the client and the clinician from gaining meaningful access to the areas of deepest vulnerability and suffering, particularly with a trauma history.  Taking a multiplicity of the self-perspective is a useful approach to assist both clients and clinicians in understanding how to collaboratively explore all aspects of what appear to be therapeutic impasses. Using the authentic therapeutic alliance and applying nuanced experiential, somatic, emotion-focused, and family systems-based approaches, can facilitate access to the “parts” of self that rely on substance use to cope.

Target Audience
  • • Counselor
  • • Marriage & Family Therapist
  • • Psychologist
  • • Social Worker
  • • Substance Use Disorder Professionals
Educational Goal

The educational goal of this workshop is to provide clinicians with a comprehensive understanding of how to navigate the complex interplay between trauma and substance use disorders by exploring therapeutic approaches that strengthen the therapeutic alliance, address clinical barriers, and utilize experiential, somatic, and novel interventions to promote healing.

Learning Objectives

At the end of this course, participants will be able to:

  • Define at least 2 clinical barriers and at least 2 treatment assumptions uniquely manifesting for co-occurring substance use and trauma treatment.

  • Examine 2 ways to strengthen the therapeutic alliance from an attachment-based lens that emphasizes resiliency and de-pathologizes the concept of "resistance" for dually-diagnosed individuals.

  • Summarize the range of clinical strategies and novel, somatic-based interventions (KAP, SE) that promote safety, support emotional intimacy, and invite exploration of parts of self that were alienated through trauma/substance use.

References

  • Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of psychopharmacology (Oxford, England), 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019

  • Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological reviews, 71(3), 316-344

  • Center for Disease Control & Prevention (2023); Center for Disease Control & Prevention, WONDER Online Database, 2023; https://nida.nih.gov/researchtopics/trends-statistics/overdose-death-rates

  • Cloitre M, Courtois CA, Charuvastra A, Carapezza R, Stolbach BC, Green BL. (2011). Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. J Trauma Stress, (24), 615–627.

  • Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020). A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. The American journal of psychiatry, 177(2), 125–133. https://doi.org/10.1176/appi.ajp.2019.19070684

  • Dakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014). The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biological psychiatry, 76(1), 40–46. https://doi.org/10.1016/j.biopsych.2013.08.009

  • Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of contextual behavioral science, 15, 39–45. https://doi.org/10.1016/j.jcbs.2019.11.004

  • Deyama, S., & Duman, R. S. (2020). Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacology, biochemistry, and behavior, 188, 172837. https://doi.org/10.1016/j.pbb.2019.172837

  • Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of psychoactive drugs, 51(2), 189–198. https://doi.org/10.1080/02791072.2019.1587556

  • Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of pain research, 15, 1691–1706. https://doi.org/10.2147/JPR.S360733

  • Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 Oct 5;338(6103):68-72. doi: 10.1126/science.1222939. PMID: 23042884; PMCID: PMC4424898.

  • Evans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A., Jr (2018). Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biological psychiatry, 84(8), 582–590. https://doi.org/10.1016/j.biopsych.2018.01.027

  • Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71(6): 681–8.

  • Fisher, Janina. (2017). Healing the fragmented selves of trauma survivors: Overcoming internal self-alienation. Routledge.

  • Fontana, A. (1974). Terapia antidpresiva con Ci 581(ketamine). Acta Psiquiatrica Y Psicologica de America Latina, 4, 20-32.

  • Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in psychiatry, 10, 955. https://doi.org/10.3389/fpsyt.2019.00955

  • Garcia-Romeu, A. P., & Tart, C. T. (2013). Altered states of consciousness and transpersonal psychology. In H. L. Friedman & G. Hartelius (Eds.), The Wiley- Blackwell handbook of transpersonal psychology (pp. 121–140). Wiley Blackwell. https://doi.org/10.1002/9781118591277.ch6

  • Grabski, M. et al. (2022). Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. The American journal of psychiatry, 179(2), 152–162. https://doi.org/10.1176/appi.ajp.2021.21030277

  • Grof, S. (1975) Realms of the Human Unconscious: Observations from LSD Research, Viking Press, New York.

  • Gold, S., & Quiñones, M. (2022). Ketamine in contextual trauma therapy: The paradox of dissociation in (complex) PTSD. https://mindfoundation.org/cptsd-ketamine-dissociation/

  • Hamby, C. (2023) A Fraught New Frontier in Telehealth: Ketamine; New York Times, https://www.nytimes.com/2023/02/20/us/ketamine-telemedicine.html

  • Herman, JL. (1992). Complex PTSD: A syndrome in survivors of prolonged and repeated trauma. J Trauma Stress, (5), 377–391.

  • Herman, Judith. (2015). Trauma and Recovery. Basic Books. Kelmendi, B., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2022). Psychedelics. Current biology : CB, 32(2), R63–R67. https://doi.org/10.1016/j.cub.2021.12.009

  • Khantzian E.J. (2021) Psychodynamic Psychotherapy for the Treatment of Substance Use Disorders. In: el-Guebaly N., Carrà G., Galanter M., Baldacchino A.M. (eds) Textbook of Addiction Treatment. Springer, Cham.

  • Khorramzadeh, E., & Lotfy, A. O. (1973). The use of ketamine in psychiatry. Psychosomatics, 14(6), 344–346. https://doi.org/10.1016/S0033-3182(73)71306-2

  • Petri et al. (2014). Homological scaffolds of brain functional networks. J R Soc Interface. 2014 Dec 6;11(101):20140873. doi: 10.1098/rsif.2014.0873. PMID: 25401177; PMCID: PMC4223908.

  • Marich, J. (2020). Trauma and the 12 Steps, Revised and Expanded: An Inclusive Guide to Enhancing Recovery. United States: North Atlantic Books.

Intermediate
Clinical
Counselor

TPN.health has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7267. Programs that do not qualify for NBCC credit are clearly identified. TPN.health is solely responsible for all aspects of the programs.

Trusted Provider Network, LLC is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0220.

Marriage & Family Therapist

TPN.health is a CAMFT-approved continuing education provider, provider #1000101.

Trusted Provider Network, LLC is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed marriage and family therapists #MFT-0097.

Psychologist

Pending approval.

Social Worker

TPN.health, #1766, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. TPN.health maintains responsibility for this course. ACE provider approval period: 03/31/2022 – 03/31/2025. Social workers completing this course receive 1.5 continuing education credits. ASWB ACE Credit is not available in NY and NJ.

Trusted Provider Network, LLC is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0654.

Substance Use Disorder Professionals

This course has been approved by TPN.health, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #198061, TPN.health is responsible for all aspects of the programming.This course has been approved by TPN.health, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #198061, TPN.health is responsible for all aspects of the programing. Counselor Skill Group:

CE Policy
This course is fiscally sponsored by EAPA NY. There may be potential biases or conflicts of interest inherent to this relationship, and it must be disclosed to participants. These conflicts of interest have no bearing on the course content and have been resolved.
There Are No Resources to Display
If additional educational resources are added they can be found here.
  • In-Person Networking at Ascendant IOP
  • Virtual Waiting Room Opens
  • Workshop Begins
  • Workshop Ends
Note: Time designated for waiting room, lunch or breaks cannot be counted toward CE credit.
Chantelle Thomas, PhD

Dr. Chantelle Thomas, Windrose Recovery’s Executive Clinical Director, is a Clinical Psychologist specializing in addiction treatment, trauma, and health psychology. Windrose Recovery’s family of treatment programs includes The Manor, Positive Sobriety Institute, and Integrata. Dr. Thomas began her career as the Program Director for a dual-diagnosis addiction and trauma treatment center in Malibu, California. After receiving her PhD in Clinical Psychology, she completed her internship and post-doctoral fellowship in Health and Rehabilitation Psychology at the University of Wisconsin School of Medicine and Mental Health. While there, she gained specialized expertise in medical-surgical consultation, trauma-informed therapy, and chronic pain treatment. Through the University of Wisconsin’s School of Family Medicine, Dr. Thomas then joined Access Community Health Center as a behavioral health consultant for primary care physicians, where she innovated the development of a substance use disorder consultation clinic embedded within primary care. Dr. Thomas is also involved in clinical research trials at the University of Wisconsin School of Medicine and Public Health investigating psilocybin for various substance use disorders and other clinical indications. Her background in research-supported treatment modalities directly informs her ability to ensure the most effective interventions are incorporated into Windrose Recovery’s treatment programs.

Share this event with your colleagues!

Sorry, there was an issue joining the session. Please try again or contact [email protected].

Create a TPN.health Account to Register for an Event

By creating a profile, you can seamlessly access your events and obtain CE certificates directly on our platform. Your profile is a vital part of verifying and tracking your attendance, and only takes minutes to get started

Already have a TPN.health profile? Sign in below to finish registration!

Create an Account Sign In